Prognosis
Valneva to Start Final Covid Shot Trials After Positive Data
- French drugmaker’s vaccine effective and safe in early trials
- Product may go head-to-head with another vaccine in phase 3
Valneva vaccine production.
Source: Valneva SE
This article is for subscribers only.
Valneva SE plans to start final-phase trials on its Covid-19 vaccine candidate this month after positive early-stage studies, a step forward for an old-school shot that’s backed by the U.K. government.
The French company said Tuesday a phase 1/2 test produced significant levels of antibodies in more than 90% of participants and raised no safety concerns. Valneva shares rose as much as 8.4% in Paris trading.